PolyPid Ltd. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| PolyPid Ltd. | PYPD - NASDAQ |
$15.00-$17.00 | $16.00 | $16.00 | 3.8 million | 6/26/2020 |
| Barclays, BMO Capital | ||||||
Co-Manager(s): Raymond James, National Securities, ODDO BHF, AGP | ||||||
| Health Care | ||||||
Filing(s): 1st Filed 2014-10-14 Terms Added (2) 2018-03-14 2nd Filed 2018-02-08 Filed 2020-06-05 Terms Added 2020-06-22 | ||||||
PolyPid Ltd. Quote & Chart - Click for current quote - PYPD
IPO Boutique aggregates information on public companies and private companies, such as "PYPD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About PolyPid Ltd. (adapted from PolyPid Ltd. prospectus):
They are a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using our proprietary Polymer-Lipid Encapsulation matriX, or PLEX, technology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using our proprietary Polymer-Lipid Encapsulation matriX, or PLEX, technology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PYPD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.